181 related articles for article (PubMed ID: 27049176)
1. The efficacy of theophylline in preventing cisplatin-related nephrotoxicity in patients with cancer.
Karademir LD; Dogruel F; Kocyigit I; Yazici C; Unal A; Sipahioglu MH; Oymak O; Tokgoz B
Ren Fail; 2016 Jun; 38(5):806-14. PubMed ID: 27049176
[TBL] [Abstract][Full Text] [Related]
2. Urine ratio of neutrophil gelatinase-associated lipocalin to creatinine as a marker for early detection of cisplatin-associated nephrotoxicity.
Shahbazi F; Sadighi S; Dashti-Khavidaki S; Shahi F; Mirzania M
Iran J Kidney Dis; 2015 Jul; 9(4):306-10. PubMed ID: 26174458
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Neutrophil Gelatinase-Associated Lipocalin Versus B-Type Natriuretic Peptide and Cystatin C to Predict Early Acute Kidney Injury and Outcome in Patients With Acute Heart Failure.
Palazzuoli A; Ruocco G; Pellegrini M; De Gori C; Del Castillo G; Franci B; Nuti R; Ronco C
Am J Cardiol; 2015 Jul; 116(1):104-11. PubMed ID: 25943992
[TBL] [Abstract][Full Text] [Related]
4. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study.
Gaspari F; Cravedi P; Mandalà M; Perico N; de Leon FR; Stucchi N; Ferrari S; Labianca R; Remuzzi G; Ruggenenti P
Nephron Clin Pract; 2010; 115(2):c154-60. PubMed ID: 20407275
[TBL] [Abstract][Full Text] [Related]
5. Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels.
Lin HY; Lee SC; Lin SF; Hsiao HH; Liu YC; Yang WC; Hwang DY; Hung CC; Chen HC; Guh JY
Kaohsiung J Med Sci; 2013 Jun; 29(6):304-11. PubMed ID: 23684135
[TBL] [Abstract][Full Text] [Related]
6. Plasma NGAL predicts early acute kidney injury no earlier than s-creatinine or cystatin C in severely burned patients.
Rakkolainen I; Vuola J
Burns; 2016 Mar; 42(2):322-8. PubMed ID: 26724852
[TBL] [Abstract][Full Text] [Related]
7. Investigations of renal function using the level of neutrophil gelatinase-associated lipocalin associated with single-dose of cisplatin during chemotherapy.
Maghsoudi O; Mirjalili SH; Dolatabadi M; Joshaghani MF; Zarea M; Yahaghi E; Mokarizadeh A
Diagn Pathol; 2015 Jul; 10():98. PubMed ID: 26170013
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil gelatinase-associated lipocalin and cystatin C could predict renal outcome in patients undergoing kidney allograft transplantation: a prospective study.
Lebkowska U; Malyszko J; Lebkowska A; Koc-Zorawska E; Lebkowski W; Malyszko JS; Kowalewski R; Gacko M
Transplant Proc; 2009; 41(1):154-7. PubMed ID: 19249501
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients.
Ibrahim ME; Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant CL; Bowles DW; George B; Wen X; Buckley B; Aleksunes L; Joy MS
Eur J Clin Pharmacol; 2019 Jan; 75(1):51-57. PubMed ID: 30220072
[TBL] [Abstract][Full Text] [Related]
10. Serum Cystatin C as an Early Marker of Neutrophil Gelatinase-associated Lipocalin-positive Acute Kidney Injury Resulting from Cardiopulmonary Bypass in Infants with Congenital Heart Disease.
Herbert C; Patel M; Nugent A; Dimas VV; Guleserian KJ; Quigley R; Modem V
Congenit Heart Dis; 2015; 10(4):E180-8. PubMed ID: 25727405
[TBL] [Abstract][Full Text] [Related]
11. Serum neutrophil gelatinase associated lipocalin (NGAL) and cystatin C as early predictors of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention.
Padhy M; Kaushik S; Girish MP; Mohapatra S; Shah S; Koner BC
Clin Chim Acta; 2014 Aug; 435():48-52. PubMed ID: 24804935
[TBL] [Abstract][Full Text] [Related]
12. Predicting Acute Renal Injury in Cancer Patients Receiving Cisplatin Using Urinary Neutrophil Gelatinase-Associated Lipocalin and Cystatin C.
Jelinek MJ; Lee SM; Wyche Okpareke A; Wing C; Koyner JL; Murray PT; Stadler WM; O' Donnell PH
Clin Transl Sci; 2018 Jul; 11(4):420-427. PubMed ID: 29691991
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients.
Toprak Z; Cebeci E; Helvaci SA; Toprak ID; Kutlu Y; Sakin A; Tukek T
Int Urol Nephrol; 2017 Jun; 49(6):1041-1047. PubMed ID: 28255639
[TBL] [Abstract][Full Text] [Related]
14. Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values?
Bachorzewska-Gajewska H; Malyszko J; Sitniewska E; Malyszko JS; Pawlak K; Mysliwiec M; Lawnicki S; Szmitkowski M; Dobrzycki S
Kidney Blood Press Res; 2007; 30(6):408-15. PubMed ID: 17901710
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of contrast-induced nephropathy after percutaneous coronary intervention.
Liebetrau C; Gaede L; Doerr O; Blumenstein J; Rixe J; Teichert O; Willmer M; Weber M; Rolf A; Möllmann H; Hamm C; Nef H
Scand J Clin Lab Invest; 2014 Mar; 74(2):81-8. PubMed ID: 24304491
[TBL] [Abstract][Full Text] [Related]
16. Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin.
Maeda A; Ando H; Ura T; Muro K; Aoki M; Saito K; Kondo E; Takahashi S; Ito Y; Mizuno Y; Fujimura A
Anticancer Res; 2017 Sep; 37(9):5235-5239. PubMed ID: 28870959
[TBL] [Abstract][Full Text] [Related]
17. Plasma neutrophil-gelatinase-associated lipocalin and cystatin C could early diagnose contrast-induced acute kidney injury in patients with renal insufficiency undergoing an elective percutaneous coronary intervention.
Liu XL; Wang ZJ; Yang Q; Yu M; Shen H; Nie B; Han HY; Gao F; Zhou YJ
Chin Med J (Engl); 2012 Mar; 125(6):1051-6. PubMed ID: 22613530
[TBL] [Abstract][Full Text] [Related]
18. Plasma neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine, and glomerular filtration rate in patients after heart and lung transplantation.
Szewczyk M; Wielkoszyński T; Zakliczyński M; Zembala M
Transplant Proc; 2009 Oct; 41(8):3242-3. PubMed ID: 19857721
[TBL] [Abstract][Full Text] [Related]
19. Cystatin C--a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy.
Benöhr P; Grenz A; Hartmann JT; Müller GA; Blaschke S
Kidney Blood Press Res; 2006; 29(1):32-5. PubMed ID: 16582575
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Cystatin-C and radionuclidic measurement method of glomerular filtration rate in patients with lung cancer receiving cisplatin treatment.
Oc MA; Demir H; Cekmen MB; Isgoren S; Gorur GD; Bilgili U
Ren Fail; 2014 Aug; 36(7):1043-50. PubMed ID: 24846459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
